Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest: A Phase III Multi-Centre Randomised Controlled Trial (The TAME Cardiac Arrest Trial)

心脏骤停复苏后轻度高碳酸血症的靶向治疗：III 期多中心随机对照试验（TAME 心脏骤停试验）

• 批准号: nhmrc : 1119855
• 负责人: A/Pr Carol Hodgson
• 金额: $ 141.52万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-therapeutic-mild-arrest-trial/946390
• 关键词: Targeted; Therapeutic; Mild; Hypercapnia; After

The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.

TAME心脏骤停试验将研究高浓度二氧化碳（CO2）减少脑损伤的能力，比较患者“正常”和“略高于正常”的血液二氧化碳水平，并评估他们恢复正常生活任务的能力。这将是迄今为止在重症监护病房的心脏病患者中进行的规模最大的试验。这种疗法是免费的，如果证明是有效的，将改善成千上万的澳大利亚人的生活，改变临床实践，并产生重大节省。